摘要
Background: Matrix metalloproteinases 1 (MMP1) plays a role in cancer development and metastasis and high expression of MMP1 has been confirmed in various types of cancers. However, the correlation between MMP1 and prognosis and tumor-infiltration lymphocytes in breast cancer remains uncertain. In this present study, we analyzed MMP1 expression and correlation with prognosis of cancer patients in databases such as Oncomine, PrognoScan, and Kaplan-Meier plotter. In addition, we investigated the correlation of MMP1 with tumor-infiltrating immune cells in the different tumor microenvironments via Tumor Immune Estimation Resource (TIMER). Methods: MMP1 expression was analyzed via the Oncomine database and Tumor Immune Estimation Resource (TIMER) site. The prognosis of MMP1 on cancers was analyzed using Kaplan-Meier plotter, the PrognoScan database and Gene Expression Profiling Interactive Analysis (GEPIA). The correlations between MMP1 and cancer immune infiltration were investigated by TIMER. In addition, correlations betweenMMP1 expression and gene marker sets of immune infiltration were analyzed by TIMER and GEPIA. Results: MMP1 is highly expressed in most cancers and correlated to poor prognosis. MMP1 expression is significantly linked with a poorer prognosis in breast cancer (OS HR 1.78, 95% CI = 1.59 - 1.98, P −0.134, P = 2.17e-05), macrophage (R = 0.41, P = 1.11e-08), dendritic cell (R = 0.221, P = 2.92e-03) and NK cell (R = 0.213, P = 4.15e-03). Besides, MMP1 expression is significantly associated with the marker genes of immune cells (P Conclusions: Our study indicates that MMP1 is correlated with prognosis and immune infiltrating levels of CD8<sup>+</sup> T cell, CD8<sup>+</sup> T cell, macrophage, dendritic cell and NK cells in breast cancer. Besides, MMP1 expression potentially contributes to regulation of T cell, B cell, tumor-associated macrophages (TAMs), DCs, T cell exhaustion and Tregs in colon and gastric cancer. The results indicate that MMP1 can be used as a prognostic biomarker for determining prognosis and immune infiltration in breast cancer.
Background: Matrix metalloproteinases 1 (MMP1) plays a role in cancer development and metastasis and high expression of MMP1 has been confirmed in various types of cancers. However, the correlation between MMP1 and prognosis and tumor-infiltration lymphocytes in breast cancer remains uncertain. In this present study, we analyzed MMP1 expression and correlation with prognosis of cancer patients in databases such as Oncomine, PrognoScan, and Kaplan-Meier plotter. In addition, we investigated the correlation of MMP1 with tumor-infiltrating immune cells in the different tumor microenvironments via Tumor Immune Estimation Resource (TIMER). Methods: MMP1 expression was analyzed via the Oncomine database and Tumor Immune Estimation Resource (TIMER) site. The prognosis of MMP1 on cancers was analyzed using Kaplan-Meier plotter, the PrognoScan database and Gene Expression Profiling Interactive Analysis (GEPIA). The correlations between MMP1 and cancer immune infiltration were investigated by TIMER. In addition, correlations betweenMMP1 expression and gene marker sets of immune infiltration were analyzed by TIMER and GEPIA. Results: MMP1 is highly expressed in most cancers and correlated to poor prognosis. MMP1 expression is significantly linked with a poorer prognosis in breast cancer (OS HR 1.78, 95% CI = 1.59 - 1.98, P −0.134, P = 2.17e-05), macrophage (R = 0.41, P = 1.11e-08), dendritic cell (R = 0.221, P = 2.92e-03) and NK cell (R = 0.213, P = 4.15e-03). Besides, MMP1 expression is significantly associated with the marker genes of immune cells (P Conclusions: Our study indicates that MMP1 is correlated with prognosis and immune infiltrating levels of CD8<sup>+</sup> T cell, CD8<sup>+</sup> T cell, macrophage, dendritic cell and NK cells in breast cancer. Besides, MMP1 expression potentially contributes to regulation of T cell, B cell, tumor-associated macrophages (TAMs), DCs, T cell exhaustion and Tregs in colon and gastric cancer. The results indicate that MMP1 can be used as a prognostic biomarker for determining prognosis and immune infiltration in breast cancer.
出处
《Health》
CAS
2022年第2期219-235,共17页
健康（英文）
